市場調查報告書
商品編碼
353893

全球腎癌治療藥及診斷市場 - 各癌症類型、治療藥、診斷法、終端用戶、地區(2018年∼2023年)

Kidney Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球腎癌治療藥及診斷市場,預計從2018年到2023年以10.5%的年複合成長率發展。腎癌以最頻率的高的癌症之一,其中尤以腎細胞癌佔的比例這幾年慢慢增加。被這個市場主要成長要素,有高齡化,飲酒數量的增加,抽煙,生活習慣的變化,政府對腎癌治療的配合等。

本報告提供全球腎癌治療藥及診斷市場調查,市場概要,各癌症類型、治療藥、診斷法、終端用戶、地區的市場規模的變化與預測,成長要素、阻礙因素以及市場機會、課題分析,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,機會,課題分析

  • 成長要素
    • 腎癌病例數的增加
    • 製藥企業的研究開發費的增加
    • 高齡化和慢性疾病的罹患率上升
  • 阻礙因素
    • 治療相關的成本高
    • 癌症治療藥的臨床試驗的成功率低
    • 法規上的問題
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各癌症類型
    • 腎細胞癌
    • 透明細胞型腎細胞癌
    • 乳頭狀腎細胞癌
    • 嫌色素性腎細胞癌
    • 其他
  • 各治療藥物
    • Afinitor
    • Avastin
    • Inlyta
    • Nexavar
    • Proleukin
    • Votrient
    • Sutent
  • 各診斷法
    • 切片檢查
    • 靜脈瘤
    • 電腦斷層掃描
    • 腎臟、輸尿管鏡檢驗法
    • 超音波
    • 其他
  • 各終端用戶
    • 醫院
    • 製藥實驗室
    • 基因學實驗室
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • 合併及收購分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業的簡介

  • Abbott Laboratories
  • Amgen
  • Bayer Healthcare
  • Cerulean Pharma
  • F. Hoffmann-La Roche
  • Genentech
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Seattle Genetics
  • 清單並未完全網羅

第10章 市場未來展望

目錄
Product Code: 53395

The kidney cancer therapeutics & diagnostics market will show a rapid growth due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.

Key Highlights

  • According to the GLOBOCAN, the incidence of Kidney cancer is 4.5 per 100,000 in 2018, worldwide. The 5 major countries contributing to the global cancer cases are China, the United States, Russia, Germany, and Japan. These countries are found to have the highest cases of kidney cancer worldwide.
  • The increasing kidney cancer cases globally is expected to increase the demand for diagnostic methods for early-stage treatment worldwide. As per the American Cancer Society's recent estimates, in 2019, there were about 73,820 new cases of kidney cancer (44,120 in men and 29,700 in women). Kidney and renal pelvis cancer represent 4.2% of all new cancer cases in the United States. It was estimated that there were around 14,770 deaths in 2019, owing to Kidney and renal pelvis cancer.
  • Currently, there are various treatment options available and many drugs are in pipeline too, which is expected to drive the kidney cancer therapeutics and diagnostics market during the forecast period.
  • In addition, rising investments in research by various government bodies and development of novel drugs by pharmaceutical and biotechnology companies are other major contributing factors.

Key Market Trends

Clear cell RCC is Expected to be the Largest Growing Segment in the Kidney Cancer Therapeutics & Diagnostics Market

  • Clear cell renal cell carcinoma, or ccRCC, is a type of kidney cancer. Clear cell renal cell carcinoma is also called conventional renal cell carcinoma. Clear cell renal cell carcinoma is named after how the tumor looks under the microscope. The cells in the tumor look clear, like bubbles.
  • As per the National Cancer Institute of the United States, in adults, ccRCC is the most common type of kidney cancer and makes up about 80% of all renal cell carcinoma cases. ccRCC is more common in adults than in children. Renal cell carcinoma makes up 2% to 6% of childhood and young adult kidney cancer cases.
  • Patients with ccRCC may have pain or feel tired. Sometimes, patients do not have any noticeable symptoms. Symptoms can include blood in the urine, pain, weight loss, feeling tired, fever, and a lump in the side.
  • For people without symptoms, these tumors can be discovered if the person has an imaging test as well. Another method to detect ccRCC is biopsy. To check if the tumor is ccRCC, the physician performs a biopsy, taking a small sample from the tumor with a needle. The sample is studied under the microscope to see what kind of tumor it is.
  • Treatments for people with ccRCC include surgery, immunotherapy, and targeted therapy. Targeted therapy targets the changes in cancer cells that help them grow, divide, and spread. Some targeted therapies that are used to treat clear cell renal carcinoma include cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib.
  • Hence, with high prevalence of the disease and presence of diagnostic procedures and treatment therapies, the market is expected to witness growth.

North America is found to be Leading the Kidney Cancer Therapeutics & Diagnostics Market

North America dominates the global kidney cancer therapeutics and diagnostics market. The major factor driving the growth is the increasing number of kidney cancer cases. As per the GLOBOCAN 2018 statistics, estimated number of kidney cancer were 60,336 in the United States. Other factors, such as increased R&D expenditure of pharmaceutical companies and increasing incidences of aging population, are expected to lead to the growth of the market in the forecast period.

However, the region of Asia-Pacific is expected to be the fastest growing market during the forecast period. Rising patient base suffering from renal cancer, growing patient awareness and lower costs of drug production are expected to drive the growth of this market.

Competitive Landscape

There has been a presence of a considerable number of companies that are significantly contributing to the market growth. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Kidney Cancer
    • 4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
  • 4.3 Market Restraints
    • 4.3.1 High Cost Associated with Treatment
    • 4.3.2 Low Success Rate in Clinical Trials for Cancer Drugs
    • 4.3.3 Regulatory Issues
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Cancer Type
    • 5.1.1 Clear cell RCC
    • 5.1.2 Papillary RCC
    • 5.1.3 Chromophobe RCC
    • 5.1.4 Urothelial carcinoma/Transitional cell carcinoma
    • 5.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
  • 5.2 By Component
    • 5.2.1 Drugs
      • 5.2.1.1 Therapeutic Class
      • 5.2.1.1.1 Targeted Therapy
      • 5.2.1.1.2 Immunotherapy
      • 5.2.1.1.3 Other Therapeutic Class
      • 5.2.1.2 By Pharmacologic Class
      • 5.2.1.2.1 Angiogenesis Inhibitors
      • 5.2.1.2.2 Monoclonal Antibodies
      • 5.2.1.2.3 mTOR Inhibitors
      • 5.2.1.2.4 Cytokine Immunotherapy (IL-2)
    • 5.2.2 Diagnostics
      • 5.2.2.1 Biopsy
      • 5.2.2.2 Imaging Tests
      • 5.2.2.3 Blood Tests
      • 5.2.2.4 Other Diagnostics
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Amgen Inc.
    • 6.1.3 Bayer AG
    • 6.1.4 BRISTOL-MYERS SQUIBB COMPANY
    • 6.1.5 F. Hoffmann-La Roche
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 Merck KGaA (EMD Serono)
    • 6.1.8 Novartis International AG
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Seattle Genetic

7 MARKET OPPORTUNITIES AND FUTURE TRENDS